Yazar "Uzunkopru, Cihat" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    The Effect of Pregnancy on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Associated Disease Activity and Progression: A Multi-center Retrospective Study from Turkey
    (Sage Publications Ltd, 2023) Uzunkopru, Cihat; Sen, Sedat; Altintas, Ayse; Cakan, Melike; Bunul, Sena Destan; Demir, Gulsen Akman; Balci, Fatma Belgin
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
    (Elsevier Sci Ltd, 2022) Sen, Sedat; Tuncer, Asli; Ozakbas, Serkan; Uzunkopru, Cihat; Baba, Cavid; Demir, Serkan; Beckmann, Yesim
    Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known. Objective/methods: The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed. Results: The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found. Conclusion: In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection.